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Ketamine Suppresses Intestinal TLR4 Expression and NF-κB Activity in 
Lipopolysaccharide-treated Rats
Aim To investigate whether ketamine suppresses lipopolysaccharide 
(LPS)-induced increase in Toll-like receptor 4 (TLR4) expression and 
nuclear factor-kappa B (NF-κB) activity in the intestines of rats.
Methods Six groups of rats received one of the following: normal saline 
control, LPS (5 mg/kg) plus saline, LPS (5 mg/kg) plus ketamine (0.5 
mg/kg), LPS (5 mg/kg) plus ketamine (2.5 mg/kg), LPS (5 mg/kg) plus 
ketamine (10 mg/kg), or ketamine (10 mg/kg) alone. Intestinal TLR4 
mRNA expression was analyzed by reverse transcription polymerase 
chain reaction (RT-PCR), and NF-κB activity was tested by electropho-
retic mobility shift assay (EMSA) 1, 3, or 5 hours after the LPS injection.
Results Lipopolysaccharide increased TLR4 expression and NF-κB activ-
ity in the intestines of rats. Ketamine at the dosage of 0.5, 2.5, and 10 mg/
kg suppressed the LPS-induced increase in TLR4 expression and NF-κB 
activity. Ketamine alone had no effect.
Conclusion The study demonstrated that ketamine inhibits NF-κB acti-
vation in the intestines of LPS-treated rats, possibly by suppressing TLR4 
expression.
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Basic Science
Sepsis caused by Gram-negative bacteria is today an important 
medical problem, which may lead to frustratingly high mortal-
ity rates, especially after the onset of shock. Lipopolysaccharide 
(LPS), the major structural and functional component of out-
er membrane of Gram-negative bacteria, is a classic and com-
mon initiator of host innate immune responses (1). Recent stud-
ies suggest that Toll-like receptor 4 (TLR4) is a primary signal 
transducer for LPS from gram-negative bacteria (2-4). It has 
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been found in monocytes/macrophages, neutro-
phils, dendritic cells, intestinal epithelial and en-
dothelial cells, as well as in B and T cells (5). The 
engagement of TLR4 with LPS may mediate the 
activation of nuclear factor-kappa B (NF-κB) 
(6), which is in an inactive state, bound to I kap-
pa B (IκB) in the cytoplasm, under normal cellu-
lar conditions. NF-κB regulates the expression 
of many genes in innate immune responses, in-
cluding the genes encoding inflammatory cyto-
kines (7).
The important role that the intestine plays 
in the inflammatory responses to sepsis and oth-
er severe illness has been increasingly recognized. 
It has been considered that the intestinal muco-
sa can produce various inflammatory cytokines 
(8,9) and other uncertain substances, which may 
influence not only the mucosa itself but other or-
gans and tissues as well (10). Besides that, the in-
testinal barrier dysfunction may lead to bacterial 
translocation and result in endotoxemia, while 
the endotoxemia may promote bacterial trans-
location as a positive feedback (11). These events 
may accelerate the development of multiple or-
gan failure (MOF) (12,13).
Ketamine has been advocated for anesthesia 
in patients with cardiovascular compromise in-
duced by endotoxemia, because of its cardiovas-
cular stimulatory effects (14,15). Besides its an-
esthetic and cardiostimulant properties, studies 
reveal that ketamine may possess anti-inflamma-
tory effects, which are in agreement with its ben-
eficial effects in sepsis. It has been reported that 
ketamine suppresses the production of LPS-in-
duced proinflammatory cytokines in cultured 
human whole blood (16) and serum of carra-
geenan sensitized endotoxin shock mice (17,18). 
The mechanism which leads to the suppressive 
effect of ketamine on proinflammatory cyto-
kines after LPS stimulation is not clear. Previous 
studies in our laboratory suggested that ketamine 
could inhibit the LPS-induced NF-κB increase in 
peripheral blood mononuclear cells (PBMC) in 
cultured rats (19), as well as in endotoxemic rats 
(20). However, there is little information on the 
exact mechanism of the anti-inflammatory effect 
of ketamine.
Given that TLR4 activated by LPS may ini-
tiate intracellular NF-κB signaling pathway (6), 
which culminates in the expression of inflamma-
tory cytokines, and that intestine is not only the 
injured organ in sepsis but also the accelerator of 
MOF (8,12,13), with TLR4 found in intestinal 
epithelial cells, macrophages, and lymphocytes 
of the lamina propria (5,21), we designed the 
study to investigate the influence of ketamine on 
TLR4 expression in the intestines (jejunums) 
of LPS-treated rats, and find out whether this 




Male Sprague-Dawley rats (250-300 g body 
weight) used in this experiment were obtained 
from Shanghai Animal Center, Shanghai, China. 
Food and water were provided freely. The pro-
cedure followed the Institutional Animal Care 
Committee guidelines.
Experimental protocol
A total of 108 rats were randomly divided into 
six groups as follows: normal saline control, LPS 
(5 mg/kg) plus saline, LPS (5 mg/kg) plus ket-
amine (0.5 mg/kg), LPS (5 mg/kg) plus ket-
amine (2.5 mg/kg), LPS (5 mg/kg) plus ket-
amine (10 mg/kg), and ketamine (10 mg/kg) 
alone. The rats in the control group were inject-
ed with 0.9% NaCl (5 mL/kg) intraperitoneally 
(IP). The endotoxemia model was established by 
bolus injection of LPS (5 mg/kg, Escherichia coli 
O111:B4, Sigma Chemical Co., St. Louis, MO, 
USA) into the tail vein. Animals were then treat-
ed immediately with ketamine (0.5, 2.5, 10 mg/
kg) (Ketamine Hydrochloride, Hengrui Inc., 
Nanjing, China) or 0.9% NaCl (5 ml/kg) (IP). 
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The rats of the ketamine group received only 
ketamine (10 mg/kg) (IP) without LPS. Six rats 
of each group were sacrificed at 1, 3, or 5 hours 
later. The tissues from the intestines (jejunums) 
were removed and kept in liquid nitrogen for lat-
er use.
RNA extraction and reverse transcription-
polymerase chain reaction (RT-PCR)
Total RNA was extracted from each sample with 
TriPure Isolation Reagent (Roche Molecular 
Biochemicals, Basel, Switzerland), and the con-
centration was determined by spectrophotomet-
ric optical density measurement at 260 nm. Af-
ter extraction of the RNA, reverse transcription 
(RT) was performed using Reverse Transcrip-
tion System Kit (Promega, Madison, WI, USA) 
to prepare the cDNA. The primer sequences 
were: TLR4 (sense), TGGATACGTTTCCT-
TATAAG; TLR4 (antisense), GAAATGGAG-
GCACCCCTTC. Polymerase chain reaction 
(PCR) was performed with 100 μL reaction 
mixture of 2 μL of RT product, 1.5 mmol/L 
MgCl2, 2.5 U Taq DNA polymerase, 100 μmol/
L dNTP, 0.1 μmol/L primer, and 1 × Taq DNA 
polymerase magnesium-free buffer (Promega). 
Two drops of mineral oil (Sigma) were used to 
overlay the reaction mixture. PCR was conduct-
ed in a thermocycler (MiniCycler PTC 150, MJ 
Research Inc., Watertown, MA, USA) for 38 
cycles. Each PCR cycle consisted of 45 seconds 
at 95°C, 45 seconds at 54°C, and 60 seconds at 
72°C. The last cycle was followed by a final incu-
bation at 72°C for 3 minutes and cooled to 4°C. 
The polymerase chain reaction product of TLR4 
was 548 bp. RT-PCR products were electropho-
resed on a 1.5% ethidium bromide-stained aga-
rose gel and saved as digital images.
Electrophoretic mobility shift assay (EMSA)
Nuclear protein of intestinal tissue was extract-
ed and quantified as previously described (22). 
EMSA was performed using a commercial kit 
(Gel Shift Assay System, Promega). In short, 
dsDNA oligonucleotide probe for NF-κB (5′-
AGTTGAGGGGACTTTCCCAGGC-3′) 
was used, according to our previous studies (19). 
The NF-κB oligonucleotide probe was end-la-
beled with [γ-32P] ATP (Free Biotech, Beijing, 
China) with T4-polynucleotide kinase. Bind-
ing reactions were performed using nuclear ex-
tract protein (80 µg) preincubated in a binding 
buffer (9 µL), containing 10 mmol/L Tris-HCl 
(pH 7.5), 1 mmol/L MgCl2, 50 mmol/L NaCl, 
0.5 mmol/L EDTA, 0.5 mmol/L DTT, 40 mL/
L glycerol, and 0.05 g/L of poly- (deoxyinosinic 
deoxycytidylic acid) for 15 minutes at room tem-
perature. After addition of the 1 µL 32P-labeled 
oligonucleotide probe, the incubation was con-
tinued for 30 minutes at room temperature. Re-
action was stopped by adding 1µL of gel loading 
buffer, and the mixture was subjected to non-de-
naturing 40 g/L polyacrylamide gel electrophore-
sis in 0.5 × TBE buffer. The gel was dried (80°C, 
30 minutes) and exposed to Fuji x-ray film (Fuji 
Photo Film Co., Ltd, Tokyo, Japan) at -70°C. 
NF-κB activity was measured by densitometry, 
using Bandleader 3.0 software (Magnitec Ltd, 
Tel Aviv, Israel).
Statistical analysis
Data were presented as mean ± standard devia-
tion (SD). Statistical Package for the Social Sci-
ences version 11.0 (SPSS Inc., Chicago, IL, USA) 
was used for data analysis. Differences among 
groups were determined by one-way analysis of 
variance (ANOVA), followed by the least-signif-
icant-difference (LSD) post hoc test. Significance 
was defined as P<0.05.
Results
Intestinal TLR4 expression in rats was increased 
by endotoxin challenge
The intestinal TLR4 mRNA expression in rats 
was examined by RT-PCR, as described in the 
methods section. One hour after endotoxin chal-
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lenge, the TLR4 mRNA expression in the intes-
tine significantly increased, in comparison with 
the controls (Figure 1). Later on, the intestinal 
TLR4 mRNA expression gradually decreased. 
Five hours after the LPS injection, there was no 
difference in TLR4 mRNA expression between 
the LPS-treated rats and control rats (Figure 1).
Ketamine suppressed LPS-induced TLR4 increase 
in the intestines
Since the TLR4 mRNA expression was most ev-
ident 1 hour after the injection of LPS, the pro-
tective effect of ketamine was observed at this 
time point. At three (0.5, 2.5, and 10 mg/kg) 
dosage levels, ketamine significantly suppressed 
TLR4 mRNA expression, compared with the 
endotoxin group, while TLR4 mRNA expres-
sion of the intestines from the ketamine-alone 
(10 mg/kg, IP) animals did not differ from the 
controls (Figure 2).
LPS increased intestinal NF-κB activity of rats
We did EMSA to determine the intestinal NF-
κB activity of rats. The NF-κB activity was ex-
pressed as the ratio between the photodensity of 
NF-κB and the photodensity of the background. 
Endotoxin increased the NF-κB activation of the 
intestine in a time-related manner. One hour af-
ter the LPS injection, the intestinal NF-κB activ-
ity increased to 2.26 ± 0.15 relative units, com-
pared with 1.26 ± 0.11 in the control group 
(P<0.001). Then the NF-κB level decreased to 
1.72 ± 0.11 relative units at 3 hours after endo-
toxin challenge. Five hours after LPS treatment, 
there was no significant difference between the 
NF-κB activity of LPS-treated rats (1.35 ± 0.11) 
and control rats (P = 0.203) (Figure 3).
Ketamine inhibited LPS-induced NF-κB activation 
in the intestines of rats
The protective effect of ketamine on NF-κB ac-
tivity was tested 1 hour after the LPS injection, 
since the NF-κB activity reached the maximum 
at this time point. After endotoxin stimula-
tion, ketamine at the dose levels of 0.5, 2.5, and 
10 mg/kg significantly decreased the intestinal 
NF-κB activity to 1.65 ± 0.16, 1.34 ± 0.14, and 
1.28 ± 0.10 relative units, respectively (P<0.001). 
Ketamine alone (10 mg/kg IP) did not show 
significant effect on the intestinal NF-κB level 
(1.20 ± 0.09), compared with the level of control 
group (P = 0.376) (Figure 4).
Figure 1. Effects of LPS on intestinal TLR4 mRNA expression of rats. 
The rats were sacrificed 0, 1, 3, and 5 hours after LPS challenge. 
Lane 1: normal saline control; Lane 2: 1 hour after LPS injection (5 
mg/kg); Lane 3: 3 hours after LPS injection (5 mg/kg); Lane 4: 5 hours 
after LPS injection (5 mg/kg).
Figure 2. Effects of various doses of ketamine on LPS-induced incre-
ase in TLR4 mRNA expression in intestines of rats. Lane 1: normal 
saline control; Lane 2: LPS (5 mg/kg) challenge; Lane 3: LPS (5 mg/
kg) plus ketamine (0.5 mg/kg); Lane 4: LPS (5 mg/kg) plus ketamine 
(2.5 mg/kg); Lane 5: LPS (5 mg/kg) plus ketamine (10 mg/kg); Lane 6: 
ketamine (10 mg/kg) alone.
Figure 3. Intestinal NF-κB activity of rats after LPS challenge. Lane 
1: normal saline control; Lane 2: 1 hour after LPS injection (5 mg/kg); 
Lane 3: 3 hours after LPS injection (5 mg/kg); Lane 4: 5 hours after 
LPS injection (5 mg/kg) (n = 6 each group). Values are presented as 
mean±SD. Asterisk indicates P<0.001 compared with normal saline 
control group. LSD post hoc test was used for between-group diffe-
rences.
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Discussion
In this study, we demonstrated that LPS could 
increase the expression in intestinal TLR4 in rats 
in a time-related manner. Our findings also re-
vealed that LPS could enhance NF-κB activity in 
the intestines of rats. Ketamine at the dose levels 
of 0.5, 2.5, and 10 mg/kg suppressed the intesti-
nal TLR4 mRNA expression and NF-κB activity 
after LPS treatment. In addition, our results in-
dicated that ketamine itself, without LPS stim-
ulation, had no evident effects on either TLR4 
mRNA expression or NF-κB activity.
TLR4 is a member of the Toll-like recep-
tors (TLRs) family. The TLRs have been identi-
fied recently in the signal transduction induced 
by many pathogen-associated molecular pat-
terns (PAMPs) (23,24). Among 10 mamma-
lian TLRs identified, much attention has been 
focused on TLR4 because of its ability in sig-
naling innate immune response to LPS from a 
wide range of Gram-negative bacteria (3,4). LPS 
binding with LPS-binding protein (LBP) may 
be transferred to CD14 (25,26). It has been re-
ported that TLR4 is a CD14-associated trans-
membrane signal transducer, which is necessary 
for the LPS-induced cellular responses (27,28). 
Recent studies suggested that the association of 
TLR4 with myeloid differentiation factor 88 
(MyD88) results in the activation of IL-1R-asso-
ciated kinase (IRAK) and TNF receptor-associ-
ated factor (TRAF)-6 (29-31). These events may 
lead to phosphorylation of IκB and subsequent 
activation of NF-κB (32). In the present experi-
ments, we used LPS, a classic initiator of inflam-
mation and the major ligand of TLR4, as a kind 
of stimulator. Our study showed that LPS en-
hanced the TLR4 expression in the intestines of 
rats. This result is similar to the results found by 
Song et al (33) that LPS could increase TLR4 ex-
pression in human corneal epithelial cells. More-
over, we found that the TLR4 expression of the 
intestine was most significant 1 hour after endo-
toxin challenge, and then gradually decreased. So, 
the effect of ketamine on LPS-induced TLR4 in-
crease was tested 1 hour after LPS injection. Our 
results showed that ketamine at various dose lev-
els could suppress the TLR4 expression after en-
dotoxin treatment.
As mentioned above, the TLR4 signal trans-
duction may lead to NF-κB activation. NF-κB 
is ubiquitously expressed and plays the essential 
role in regulating the expression of many genes 
involved in immune and inflammatory process-
es. We performed electrophoretic mobility shift 
assay to examine NF-κB activity in this experi-
ment. Our study revealed that endotoxin could 
increase NF-κB activity, which reached its max-
imum 1 hour after LPS treatment. These results 
corresponded well with the reports by De Plaen 
et al (34,35). Previous studies from our laborato-
ry suggested that ketamine might inhibit LPS-in-
duced NF-κB activation in cultured PMBC and 
in endotoxemic rats (19,20). However, in the 
present study we tried to investigate how ket-
amine inhibited NF-κB activation. Our study 
demonstrated that ketamine at the doses of 0.5, 
2.5, and 10 mg/kg suppresses NF-κB activity af-
Figure 4. Intestinal NF-κB of rats after endotoxin treatment with or 
without the presence of ketamine. Lane 1: normal saline control; Lane 
2: LPS (5 mg/kg) challenge; Lane 3: LPS (5 mg/kg) plus ketamine (0.5 
mg/kg); Lane 4: LPS (5 mg/kg) plus ketamine (2.5 mg/kg); Lane 5: 
LPS (5 mg/kg) plus ketamine (10 mg/kg); Lane 6: ketamine (10 mg/kg) 
alone. Values are presented as mean±SD. Asterisk indicates P<0.001 
compared with normal saline control group; cross indicates P<0.001 
compared with LPS-challenged group. LSD post hoc test was used for 
between-group differences.
Croat Med J 2006;47:825-831
830
ter LPS challenge. These results were congruent 
with the effect of ketamine on LPS-induced in-
crease in TLR4 expression.
TLR4 is an essential upstream sensor for 
LPS, with a signal transduction pathway which 
may lead to NF-κB activation, and ketamine can 
suppress LPS-induced NF-κB activation. There-
fore, we hypothesized that ketamine could exert 
its anti-inflammatory effect on NF-κB activity 
in sepsis through the TLR4 signal transduction 
pathway. In our study, we demonstrated that 
LPS could enhance NF-κB activity together with 
TLR4 increase. Ketamine could suppress TLR4 
expression after endotoxin challenge, and this ef-
fect was congruous with the effect of ketamine 
on NF-κB activity. These results support our hy-
pothesis. Therefore, suppressing TLR4 expres-
sion might be a possible upstream mechanism of 
the anti-inflammatory effect of ketamine.
Since the rats were not anesthetized at the 
outset of our experiment, we did not monitor 
their arterial pressure, pulse rate, and respirato-
ry changes. Diarrhea was observed in most of the 
rats. No rats died during the experiment until 
they were sacrificed. Many others have used this 
rat endotoxemia model successfully (36).
Previous reports revealed that the production 
of inflammatory cytokines, such as tumor ne-
crosis factor (TNF), reached the maximum 1 to 
2 hours after LPS treatment in the sera of mice 
(37,38), then decreased, and were hardly detect-
able after 6 hours. In our study, we tested the 
TLR4 expression and NF-κB activity, which may 
serve as upstream elements in inflammatory pro-
cesses at 1, 3, and 5 hours after endotoxin chal-
lenge, and our results corresponded with previ-
ous reports.
Sakai et al (39) reported that ketamine at the 
doses of 2, 5, or 10 mg/kg could inhibit LPS-in-
duced NF-κB activation in intact brain cells of 
mice. Our results implied that ketamine at the 
dose levels of 0.5, 2.5, and 10 mg/kg could in-
hibit TLR4 expression and NF-κB activity in 
the intestines of rats in endotoxemia, which sup-
ported their findings. However, the clinic use of 
ketamine as a kind of anti-inflammatory medi-
cine still needs further careful evaluation.
In conclusion, this study demonstrated that 
LPS could increase TLR4 expression and NF-
κB activity in the intestines of rats. Ketamine at 
the doses of 0.5, 2.5, and 10 mg/kg could inhibit 
intestinal NF-κB activity of rats after endotoxin 
challenge. Suppressing TLR4 expression might 
be an upstream mechanism for this inhibito-
ry effect of ketamine on NF-κB in sepsis. Better 
understanding of this mechanism may lead to a 
more effective application of ketamine, but fur-
ther investigation is still required.
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